Stool testing for the early detection of pancreatic cancer: rationale and current evidence

References

• Brenner H, Gondos A, Arndt V. Recent major progress in long-term cancer patient survival disclosed by modelled period analyses. J. Clin. Oncol.25, 3274–3280 (2007).
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55, 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Tsunoda T, Yamamoto Y, Kimoto M et al. Staging and treatment for patients with pancreatic cancer. How small is an early pancreatic cancer? J. Hepatobiliary Pancreat. Surg.5, 128–132 (1998).
   PubMedGoogle Scholar
• Ariyama J, Suyama M, Ogawa K et al. The detection and prognosis of small pancreatic carcinoma. Int. J. Pancreatol.7, 37–47 (1990).
   PubMedGoogle Scholar
• Canto MI, Goggins M, Yeo CJ et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin. Gastroenterol. Hepatol.2, 606–621 (2004).
   PubMed Web of Science ®Google Scholar
• Canto MI, Goggins M, Hruban RH et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin. Gastroenterol. Hepatol.4, 766–781 (2006).
   PubMed Web of Science ®Google Scholar
• DeWitt J, Devereaux B, Chriswell M et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann. Intern. Med.141, 753–763 (2004).
   PubMed Web of Science ®Google Scholar
• Dewitt J, Devereaux BM, Lehman GA, Sherman S, Imperiale TF. Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. Clin. Gastroenterol. Hepatol.4, 717–725 (2006).
   PubMed Web of Science ®Google Scholar
• Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C. Reported family aggregation of pancreatic cancer within a population-based case–control study in the Francophone community in Montreal, Canada. Int. J. Pancreatol.10, 183–196 (1991).
   PubMedGoogle Scholar
• Silverman DT, Schiffman M, Everhart J et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br. J. Cancer80, 1830–1837 (1999).
   PubMed Web of Science ®Google Scholar
• De Angelis C, Repici A, Carucci P et al. Pancreatic cancer imaging: the new role of endoscopic ultrasound. JOP8(Suppl. 1), 85–97 (2007).
   PubMedGoogle Scholar
• Brune K, Abe T, Canto M et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am. J. Surg. Pathol.30, 1067–1076 (2006).
   PubMed Web of Science ®Google Scholar
• Goggins M, Canto M, Hruban R. Can we screen high-risk individuals to detect early pancreatic carcinoma? J. Surg. Oncol.74, 243–248 (2000).
   PubMed Web of Science ®Google Scholar
• Laurell H, Bouisson M, Berthelemy P et al. Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. World J. Gastroenterol.12, 3344–3351 (2006).
   PubMed Web of Science ®Google Scholar
• Arvanitakis M, Van Laethem JL, Parma J, De Maertelaer V, Delhaye M, Deviere J. Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation. Endoscopy36, 535–542 (2004).
   PubMed Web of Science ®Google Scholar
• Costentin L, Pages P, Bouisson M et al. Frequent deletions of tumor suppressor genes in pure pancreatic juice from patients with tumoral or nontumoral pancreatic diseases. Pancreatology2, 17–25 (2002).
   PubMed Web of Science ®Google Scholar
• Zhou L, Lu Z, Yang A et al. Comparative proteomic analysis of human pancreatic juice: methodological study. Proteomics7, 1345–1355 (2007).
   PubMed Web of Science ®Google Scholar
• Yan L, McFaul C, Howes N et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology128, 2124–2130 (2005).
   PubMed Web of Science ®Google Scholar
• Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann. Intern. Med.131(4) 247–255 (1999). Erratum: Ann. Intern. Med.132, 419 (2000).
   PubMed Web of Science ®Google Scholar
• Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19–19 as a screening test for pancreatic cancer in an asymptomatic population. J. Gastroenterol. Hepatol.19, 182–186 (2004).
   PubMed Web of Science ®Google Scholar
• Koopmann J, Rosenzweig CN, Zhang Z et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin. Cancer Res.12, 442–446 (2006).
   PubMed Web of Science ®Google Scholar
• Melle C, Ernst G, Escher N et al. Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin. Chem.53, 629–635 (2007).
   PubMed Web of Science ®Google Scholar
• Laird PW. The power and the promise of DNA methylation markers. Nat. Rev. Cancer3, 253–266 (2003).
   PubMed Web of Science ®Google Scholar
• Leung WK, To KF, Man EP et al. Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin. Chem.50, 2179–2182 (2004).
   PubMed Web of Science ®Google Scholar
• Leung WK, To KF, Man EP et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am. J. Gastroenterol.100, 2274–2279 (2005).
   PubMed Web of Science ®Google Scholar
• Wang JY, Hsieh JS, Chang MY et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J. Surg.28, 721–726 (2004).
   PubMed Web of Science ®Google Scholar
• Silva JM, Dominguez G, Garcia JM et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res.59, 3251–3256 (1999).
   PubMed Web of Science ®Google Scholar
• Leung WK, To KF, Man EP et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am. J. Gastroenterol.102, 1070–1076 (2007).
   PubMed Web of Science ®Google Scholar
• Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology127, 422–427 (2004).
   PubMed Web of Science ®Google Scholar
• Vernon SW. Participation in colorectal cancer screening: a review. J. Natl Cancer Inst.89, 1406–1422 (2003).
   Google Scholar
• Maitra A, Fukushima N, Takaori K, Hruban RH. Precursors to invasive pancreatic cancer. Adv. Anat. Pathol.12, 81–91 (2005).
   PubMed Web of Science ®Google Scholar
• Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res.36, 2690–2698 (1976).
   PubMed Web of Science ®Google Scholar
• Kozuka S, Sassa R, Taki T et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer43, 1418–1428 (1979).
   PubMedGoogle Scholar
• Lowenfels AB, Maisonneuve P, Cavallini G et al; International Pancreatitis Study Group. Pancreatitis and the risk of pancreatic cancer. N. Engl. J. Med.328, 1433–1437 (1993).
   PubMed Web of Science ®Google Scholar
• Brand RE, Lerch MM, Rubinstein WS et al. Participants of the Fourth International Symposium of Inherited Diseases of the Pancreas. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut56, 1460–1469 (2007).
   PubMed Web of Science ®Google Scholar
• Howes N, Lerch MM, Greenhalf W et al. European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC). Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin. Gastroenterol. Hepatol.2, 252–261 (2004).
   PubMed Web of Science ®Google Scholar
• Wong T, Howes N, Threadgold J et al. Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients. Pancreatology1, 486–509 (2001).
   PubMed Web of Science ®Google Scholar
• Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res.54, 3568–3573 (1994).
   PubMed Web of Science ®Google Scholar
• Berndt C, Haubold K, Wenger F et al.K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. Clin. Chem.44, 2103–2107 (1998).
   PubMed Web of Science ®Google Scholar
• Wenger FA, Zieren J, Peter FJ, Jacobi CA, Muller JM. K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis. Langenbecks Arch. Surg.384, 181–186 (1999).
   PubMed Web of Science ®Google Scholar
• Lu X, Xu T, Qian J, Wen X, Wu D. Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer. Chin. Med. J. (Engl.)115(11), 1632–1636 (2002).
   PubMed Web of Science ®Google Scholar
• Wu X, Lu XH, Xu T et al. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin. J. Dig. Dis.7, 170–174 (2006).
   PubMedGoogle Scholar
• Pezzilli R, Barassi A, Melzi d’Eril G et al. The search of the stool and blood K-ras mutations in patients with pancreatic mass. Pancreas33, 199–200 (2006).
   PubMed Web of Science ®Google Scholar
• Haug U, Hillebrand T, Bendzko P et al. Mutant-enriched PCR and allele-specific hybridization reaction to detect K-ras mutations in stool DNA: high prevalence in a large sample of older adults. Clin. Chem.53, 787–790 (2007).
   PubMed Web of Science ®Google Scholar
• Hruban RH, van Mansfeld AD, Offerhaus GJ et al.K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol.143, 545–554 (1993).
   PubMed Web of Science ®Google Scholar
• Haug U, Brenner H. New stool tests for colorectal cancer screening: a systematic review focusing on performance characteristics and practicalness. Int. J. Cancer117, 169–176 (2005).
   PubMed Web of Science ®Google Scholar
• Müller HM, Oberwalder M, Fiegl H et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet363, 1283–1285 (2004).
   PubMed Web of Science ®Google Scholar
• Belshaw NJ, Elliott GO, Williams EA et al. Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer. Cancer Epidemiol. Biomarkers Prev.13, 1495–1501 (2004).
   PubMed Web of Science ®Google Scholar
• Leung WK, To KF, Man EP et al. Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin. Chem.50, 2179–2182 (2004).
   PubMed Web of Science ®Google Scholar
• Petko Z, Ghiassi M, Shuber A et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin. Cancer Res.11, 1203–1209 (2005).
   PubMed Web of Science ®Google Scholar
• Lenhard K, Bommer GT, Asutay S et al. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin. Gastroenterol. Hepatol.3, 142–149 (2005).
   PubMed Web of Science ®Google Scholar
• Itzkowitz SH, Jandorf L, Brand R et al. Improved fecal DNA test for colorectal cancer screening. Clin. Gastroenterol. Hepatol.5, 111–117 (2007).
   PubMed Web of Science ®Google Scholar
• Huang ZH, Li LH, Yang F, Wang JF. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J. Gastroenterol.13, 950–954 (2007).
   PubMed Web of Science ®Google Scholar
• Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J. Hepatobiliary Pancreat. Surg.13, 286–295 (2006).
   PubMedGoogle Scholar
• Goggins M. Molecular markers of early pancreatic cancer. J. Clin. Oncol.23, 4524–4531 (2005).
   PubMed Web of Science ®Google Scholar
• Olson J, Whitney DH, Durkee K, Shuber AP. DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn. Mol. Pathol.14, 183–191 (2005).
   PubMedGoogle Scholar
• Whitney D, Skoletsky J, Moore K et al. Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J. Mol. Diagn.6, 386–395 (2004).
   PubMed Web of Science ®Google Scholar